Deal framework and scope
Altria Group Inc.'s subsidiary Philip Morris USA Inc. entered into a contract manufacturing arrangement with non-U.S. affiliates of Philip Morris International Inc. for combustible cigarettes, according to reporting published on August 24, 2026. The arrangement is designed to enhance the efficiency and operational capabilities of PM USA's traditional tobacco product operations. The two companies said they will continue to operate independently and retain responsibility for their respective commercialization, distribution and regulatory activities. PMI emphasized that it has not commercialized combustible cigarettes in the United States and has no plans to do so, and the manufacturing agreement does not change that position.
Timeline and financial impact
The first shipments under the agreement are expected to begin in early 2027, subject to operational readiness and applicable regulatory requirements. Both companies indicated they do not expect the arrangement to have a material impact on their respective 2026 financial results. Altria said the deal supports its 2028 Enterprise Goals by enhancing operational capabilities, generating economic benefits to back investment in its broader vision and strengthening capabilities that could be transferable to its international nicotine efforts. Altria shares rose about 4% following the announcement, based on market trading reported on August 24, 2026.
PMI's parallel U.S. manufacturing expansion
The combustible cigarette arrangement comes as PMI continues a separate push to expand its U.S. manufacturing and supply chain footprint around smoke-free products. The company opened a $1.2 billion ZYN manufacturing campus in Aurora, Colorado — an approximately 780,000-square-foot facility that brings production, packaging, warehousing and distribution together at one site and represents PMI's first greenfield manufacturing and production complex in the United States. PMI U.S. is also expanding production capacity at the Aurora campus to support ZYN's continued growth in U.S. and international markets.
PMI's broader U.S. investment portfolio
Since 2022, PMI U.S. has invested more than $1 billion in American manufacturing, operational capabilities and personnel costs through Sept. 30, 2025, according to company figures cited on August 24, 2026. Those investments include the $600 million ZYN manufacturing facility in Aurora, a $232 million expansion of its existing ZYN production site in Owensboro, Kentucky, and more than $37 million to support expanded operations at its Wilson, North Carolina manufacturing facility. In March 2026, PMI U.S. also announced a roughly $50 million investment in a new Business Solutions Center in Tampa, Florida, which is designed to consolidate business solutions, distribution operations and customer service functions and is expected to create approximately 180 direct and indirect high-skilled jobs.
Strategic positioning of both companies
PMI described itself as an international consumer goods company focused on building a smoke-free future while expanding its portfolio beyond tobacco and nicotine. Its current portfolio primarily consists of cigarettes and smoke-free products, including heated tobacco, nicotine pouch and e-vapor products. PMI's smoke-free products are available in more than 105 markets and, as of Dec. 31, 2025, were used by an estimated 43 million legal-age consumers worldwide. Smoke-free products accounted for approximately 42% of PMI's total net revenues in the second quarter of 2026. Since 2008, the company has invested more than $16 billion in developing, scientifically substantiating and commercializing smoke-free products for legal-age adults who would otherwise smoke. Altria, headquartered in Richmond, Virginia, holds a portfolio of combustible and smoke-free nicotine products for U.S. consumers age 21 and older.
Share this article
